Hemogenyx Pharmaceuticals (LSE:HEMO) announced that the Data Safety Monitoring Board (DSMB) has authorized the continuation of its Phase I clinical trial for HG-CT-1, the company’s proprietary CAR-T therapy for acute myeloid leukemia (AML). The approval clears the path for dose escalation and the initiation of pediatric patient recruitment, marking a key advancement in the program’s clinical development.
This milestone represents a significant de-risking event for HG-CT-1, reinforcing its safety profile and paving the way for broader clinical validation. Successful progression at this stage could strengthen Hemogenyx’s position in the cell therapy market, attract greater investor confidence, and enhance the company’s reputation as an innovator in AML treatment.
The company stated that the positive DSMB review demonstrates confidence in the therapy’s clinical design and underlines its potential to deliver improved efficacy outcomes in both adult and pediatric patient populations.
More about Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a London-based biopharmaceutical company with subsidiaries in New York City. It focuses on developing transformative therapies for blood and autoimmune diseases, leveraging cutting-edge technologies including CAR-T cell therapy, bi-specific antibody platforms, and humanized mouse models to accelerate novel drug discovery and clinical innovation.
Leave a Reply